Microfluidics to Participate in POWREX Corporation's Annual New Pharmaceutical Technology and Engineering Conference

Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation (OTCBB: MFLU), recently was invited to participate in POWREX Corporation's annual New Pharmaceutical Technology and Engineering Conference, which is among Japan's premier annual pharmaceutical events.

Microfluidics Chief Technology Officer Thomai "Mimi" Panagiotou, Ph.D., delivered a presentation on production of nanomaterials for pharmaceutical applications using high shear fluid processors. Primarily Dr. Panagiotou featured innovative bottom-up Microfluidics Reaction Technology (MRT) for continuous crystallization, chemical reactions and process intensification.

Held on July 22-23 at POWREX's corporate headquarters in Tokyo, Japan, the symposium was attended by more than 350 senior pharmaceutical executives. Dr. Panagiotou joined fellow keynote speakers from Merck and Co., GlaxoSmithKline, Takeda Pharmaceutical Company, Boehringer Ingelheim and Novartis along with other leaders from industry, academia and international government organizations. Topics ranged from new quality paradigms in pharmaceutical manufacturing to advanced drug delivery methodologies. The thought-provoking event featured engaging and thoughtful dialogues and coincided with a celebration of POWREX's 55th company anniversary.

The conference doubled as the formal introduction of Microfluidics technology to Japan. POWREX is Microfluidics' exclusive distributor for Japanese pharmaceutical, biotechnology and energy industries.

Dr. Panagiotou will next speak at GlaxoSmithKline Research & Development department in Stevenage, UK, on September 23, followed by a talk at the Material Research Society meeting in Boston, MA, to be held from November 30-December 4.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback